| Literature DB >> 31445517 |
Edwin Kniha1, Adelheid G Obwaller1,2, Gerhard Dobler3, Wolfgang Poeppl4,5, Gerhard Mooseder5, Julia Walochnik6.
Abstract
BACKGROUND: Phleboviruses are mainly transmitted by sand flies and infections can result in various symptoms, including meningitis and meningoencephalitis. In endemic regions, seroprevalences in humans and animals are high. Military personnel on missions in endemic areas are at increased risk of infection, however, for soldiers from central European countries, data are scarce. The aims of this study were to determine the exposure to phleboviruses of Austrian soldiers returning from missions abroad and to assess potential risk factors. A retrospective serological study was performed with sera of 753 healthy Austrian soldiers returning from missions in Bosnia and Herzegovina (BIH, n = 61), Kosovo (n = 261), Syria (n = 101) and Lebanon (n = 63) and of soldiers prior to their missions (n = 267).Entities:
Keywords: Balkans; Middle East; Military; Risk factors; Sand fly; Sand fly fever
Mesh:
Substances:
Year: 2019 PMID: 31445517 PMCID: PMC6708154 DOI: 10.1186/s13071-019-3674-6
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Seroprevalences by age
| Age group (years) | Positive/Total (%) | OR | 95% CI | ||
|---|---|---|---|---|---|
| Operational areas | < 30 | 33/252 (13.1) | Reference | ||
| 30–39 | 8/95 (8.4) | 0.6 | 0.2–1.4 | 0.2 | |
| 40–49 | 16/99 (16.2) | 1.3 | 0.6–2.5 | 0.5 | |
| > 50 | 4/40 (10.0) | 0.7 | 0.2–2.0 | 0.6 | |
| Without prior mission | < 30 | 10/232 (4.3) | Reference | ||
| 30–39 | 2/26 (7.7) | 1.8 | 0.2–9.1 | 0.4 | |
| 40–49 | 0/7 (0) | – | – | – | |
| > 50 | 0/2 (0) | – | – | – |
Titers by operational areas
| 1:10 | 1:20 | 1:40 | 1:80 | 1:100 | 1:320 | 1:1000 | Total | ||
|---|---|---|---|---|---|---|---|---|---|
| IgG | Without prior mission | 8/267 (2.99%) | 3/267 (1.12%) | 4/267 (1.50%) | 4/267 (1.50%) | 3/267 (1.12%) | 9/267 (3.37%) | – | 31/267 (11.6%) |
| BIH | – | 1/61 (1.64%) | 1/61 (1.64%) | 2/61 (3.28%) | 3/ 61 (4.92%) | – | – | 7/61 (11.47%) | |
| Kosovo | 23/261 (8.81%) | 3/261 (1.15%) | 11/261 (4.21%) | 3/261 (1.15%) | 6/261 (2.30%) | 7/261 (2.68%) | 1/261 (0.38%) | 54/261 (20.69%) | |
| Syria | 3/101 (2.97%) | 2/101 (1.98%) | 4/101 (3.96%) | 1/101 (0.99%) | 3/ 101 (2.97%) | 5/101 (4.95%) | – | 18/101 (17.82%) | |
| Lebanon | 1/63 (1.59%) | 1/63 (1.59%) | – | 1/63 (1.59%) | 3/63 (4.76%) | – | 3/63 (4.76%) | 9/63 (14.28%) | |
| IgMa | Without prior mission | 2/31 (6.45%) | 3/31 (9.68%) | 3/31 (9.68%) | 2/31 (6.45%) | – | – | 10/31 (32.25%) | |
| BIH | – | – | – | – | – | – | – | 0/7 (0.00%) | |
| Kosovo | 5/54 (9.26%) | 5/54 (9.26%) | – | 2/54 (3.70%) | 4/54 (7.41%) | – | – | 16/54 (29.63%) | |
| Syria | – | 1/18 (5.55%) | – | 1/18 (5.55%) | 1/18 (5.55%) | – | – | 3/18 (16.67%) | |
| Lebanon | – | 1/9 (11.11%) | – | – | – | – | – | 1/9 (11.11%) |
aOnly IgG positive samples tested
Seroprevalences by operational areas
| Titer ≥ 1:10 | Titer ≥ 1:20 | Titer ≥ 1:100 | ||||
|---|---|---|---|---|---|---|
| IgG positive/Total (%) | OR/95% CI | IgG positive/Total (%) | OR/95% CI | IgG positive/Total (%) | OR/95% CI | |
| Soldiers before missions | 31/267 (11.6) | Reference | 23/267 (8.6%) | Reference | 12/267 (4.5) | Reference |
| BIH | 7/61 (11.5) | 1.0/0.4–2.5 (1.0) | 7/61 (11.5%) | 1.4/0.5–3.5 (0.46) | 3/61 (4.9) | 1.1/0.2–4.3 (1.0) |
| Kosovo | 54/261 (20.7) | 1.9/1.2–3.2 (0.006)* | 31/261 (11.9%) | 1.5/0.8–2.7 (0.25) | 14/261 (5.4) | 1.2/0.5–2.9 (0.70) |
| Syria | 18/101 (17.8) | 1.7/0.8–3.2 (0.12) | 15/101 (14.9%) | 2.0/0.9–4.3 (0.05)* | 8/101 (7.9) | 1.8/0.6–5.0 (0.20) |
| Lebanon | 9/63 (14.3) | 1.3/0.5–3.0 (0.50) | 8/63 (12.7) | 1.7/0.6–4.2 (0.22) | 6/63 (9.5) | 2.23/0.7–6.8 (0.13) |
* Significant result (P < 0.05)
Risk factors for Phlebovirus seropositivity during a mission
| Risk factors | OR | 95% CI | |
|---|---|---|---|
| Missions | |||
| Prior mission | 0.80 | 0.5–1.4 | 0.50 |
| Kosovo | 0.70 | 0.3–1.3 | 0.29 |
| Syria | 1.22 | 0.6–2.7 | 0.60 |
| Bosnia | 1.33 | 0.5–2.9 | 0.53 |
| Symptoms | |||
| Symptoms | 1.90 | 1.1–3.4 | 0.03* |
| Fever | 2.30 | 1.03–4.6 | 0.03* |
| Limb pain | 1.03 | 0.3–3.1 | 1 |
| Vacation | 1.88 | 0.9–4.1 | 0.12 |
| Outdoor activities | |||
| Sports | 1.40 | 0.5–4.6 | 0.70 |
| Running | 1.90 | 0.9–4.4 | 0.08a |
| Mountaineering | 1.17 | 0.6–2.1 | 0.60 |
| Cycling | 0.97 | 0.5–2.0 | 1.0 |
| Football | 1.00 | 0.1–4.5 | 1.0 |
| Animal contact | |||
| Dog | 1.10 | 0.6–2.0 | 0.80 |
| Cat | 1.40 | 0.7–2.6 | 0.27 |
| Rodent | 1.40 | 0.03–12.8 | 0.50 |
| Pets | 1.12 | 0.7–2.2 | 0.50 |
| | 1.50 | 0.7–3.0 | 0.20 |
| | 2.70 | 1.2–5.8 | 0.009* |
| | 0.60 | 0.1–2.0 | 0.60 |
* Significant result (P < 0.05)
aStrong trend
Seroprevalence by duration of mission
| Duration (months) | Total | IgG positive (%) | OR | 95% CI | |
|---|---|---|---|---|---|
| < 6 | 84 | 7 (8.33) | Reference | ||
| 6–11 | 315 | 38 (12.06) | 1.5 | 0.6–4.2 | 0.44 |
| > 11 | 87 | 16 (18.39) | 2.5 | 0.9–7.5 | 0.07 |
Seropositivity by risk of infection (sand fly activity)
| Risk of infection | Total | IgG positive (%) | OR | 95% CI | |
|---|---|---|---|---|---|
| Low | 275 | 32 (11.64) | Reference | ||
| Medium | 116 | 12 (10.34) | 0.9 | 0.4–1.8 | 0.90 |
| High | 95 | 17 (17.89) | 1.7 | 0.8–3.3 | 0.16 |
Note: risk of infection calculated: high, June, July and August; medium, two of three (June, July, August); low, one of three (June, July, August) and other months
Seroprevalences of Phlebovirus serotypes
| SFNV complex | SFSV complex | ||||
|---|---|---|---|---|---|
| TOSV | SFNV | SFSV | CYPV | ||
| IgG | Without prior mission | 22/31 (71.0%) | 2/31 (6.5%) | 7/31 (22.5%) | – |
| Operational areas | 45/88 (51.1%) | 2/88 (2.3%) | 39/88 (44.3%) | 2/88 (2.3%) | |
| IgM | Without prior mission | 10/10a (100%) | – | – | – |
| Operational areas | 13/20a (65.0%) | – | 7/20a (35.0%) | – | |
aPercentage of the tested IgG positive samples